Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2696 · · 10 pages · English
Summary by 6ix AI
It reports on the movements in authorized and registered share capital, as well as issued shares and treasury shares. The total authorized share capital at the end of the month is reported, along with confirmations regarding public float sufficiency. Additionally, it includes details on share options and any agreements related to issuing shares.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Shanghai Henlius Biotech, Inc. on 6ix
Earlier from Shanghai Henlius Biotech
- List of directors and their roles and functions
- (1) Changes in non-executive director and independent non-executive director (2) appointment of chairman of the board and changes in composition of the board committees
- Interim report 2026
- Voluntary announcement - collaboration and license agreement with amberstone for two T Cell Engager products
- Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
Follow Shanghai Henlius Biotech into a list and get an email when it puts out news.
Follow Shanghai Henlius Biotech